FDA Approves First Implantable Continuous Glucose Monitor FDA Approves First Implantable Continuous Glucose Monitor

The Eversense is implanted under the skin in a short office procedure and worn for up to 90 days.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news